SAGE News and Press, Sage Therapeutics Inc. From 08/31/23

2023-08-31 07:22:43 ET More on Sage Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity Sage Therapeutics, Inc. ( SAGE ) Business Update Call (Transcript) Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market Sage Therapeutic...

Potential growth catalysts include planned 4Q 2023 launch of ZURZUVAE (zuranolone) and expected data read-outs for SAGE-718 and SAGE-324 in 2024 Approximately 40% workforce reduction supports focus on agile execution of business priorities Strengthened financial position w...

2023-08-24 05:10:00 ET News from the Food and Drug Administration (FDA) can often make or break a stock. This month, it broke Sage Therapeutics (NASDAQ: SAGE) . Although the company obtained approval for its depression treatment zuranolone, it was for postpartum depression only....

San Francisco, California--(Newsfile Corp. - August 23, 2023) - Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/sage Contact An Attorney Now: SAGE@hbsslaw.com ...

2023-08-20 23:55:36 ET Summary The S&P 500 experienced a strong reversal to end the week, suggesting a buoyant start to the next week. The market is anticipating harsh rhetoric from Powell at Jackson Hole, with expectations of one more rate hike and no rate cuts until 2025. ...

2023-08-16 14:13:34 ET BofA Securities has upgraded Axsome Therapeutics ( NASDAQ: AXSM ) to neutral, citing an improved outlook for the company's drug Auvelity for major depressive disorder, or MDD. The investment bank said it was upgrading the stock primarily because Axsome's M...

San Francisco, California--(Newsfile Corp. - August 15, 2023) - Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/sage Contact An Attorney Now: SAGE@hbsslaw.com 844-...

2023-08-14 16:38:10 ET Summary Sage Therapeutics, Inc. has a virtual monopoly in treating postpartum depression, a condition that affects 15%-20% of postpartum women. The company's pipeline focuses on treating CNS disorders by modulating GABA and NMDA receptors. The major depr...

2023-08-11 12:32:11 ET More on Sage Therapeutics Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain RBC Capital cuts Sage to sector perform, calls FDA decision "major setback"...

2023-08-11 11:23:53 ET Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence . The pharmaceutical company's stock closed last week at $36.10, then fell to a 52-wee...